Wave Life Sciences (WVE) Cash from Financing Activities (2015 - 2026)

Wave Life Sciences' Cash from Financing Activities history runs 12 years deep, the most recent figure standing at $2.5 million for Q1 2026.

• Quarterly Cash from Financing Activities fell 39.18% year-over-year to $2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $486.6 million (up 99.81% YoY) and the FY2025 annual result came in at $488.2 million, up 92.3% from the prior year.
• Cash from Financing Activities was $2.5 million for Q1 2026 at Wave Life Sciences, down from $439.7 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $439.7 million in Q4 2025 and bottomed at $17000.0 in Q3 2022.
• A 5-year average of $55.6 million and a median of $11.7 million in 2025 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities plunged 99.84% — and 2023, when it jumped 170740.0%.
• Wave Life Sciences' Cash from Financing Activities stood at $55000.0 in 2022, then soared by 170740.0% to $94.0 million in 2023, then slumped by 62.77% to $35.0 million in 2024, then surged by 1156.95% to $439.7 million in 2025, then tumbled by 99.43% to $2.5 million in 2026.
• Business Quant data shows WVE's Cash from Financing Activities at $2.5 million in Q1 2026, $439.7 million in Q4 2025, and $32.7 million in Q3 2025.